Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New model could predict liver metastases in stomach cancer patients

NCT ID NCT06023966

Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a risk scoring model to predict whether stomach cancer might spread to the liver after surgery. Researchers followed 120 patients who had their stomach cancer removed to see if the model could accurately identify those at higher risk. The goal is to help doctors personalize follow-up care and catch liver metastases early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Sep 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patietns who were diagnosed with gastric cancer pathologically and underwent curative gastrectomy.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Received curative gastrectomy (D2 lymph node dissection); 2. Gastric cancer without distant organ metastasis, distant lymph node metastasis and peritoneal implantation (M0) confirmed by postoperative pathology; 3. No hepatic tumors and other occupying diseases, no chronic diseases such as cirrhosis and hepatitis, no hepatic schistosomiasis, no hepatic echinococcosis, no hepatic tuberculosis, and no severe fatty liver disease before the curative surgery; 4. No history of intraperitoneal chemotherapy; 5. No other serious concomitant diseases with satisfactory organ function; 6. No history of other malignant tumors; 7. Comply with the protocol during the whole study period; 8. Sign informed consent and permission of withdraw in the whole study period; 9. Estimation the overall survival after surgery no less than 12 months; 10. Consent to analysis of clinicopathological data and prognostic follow up; 11. Karnofsky Performance Scores (KPS) more than 60. Exclusion Criteria: 1. Special histological types of gastric cancer (neuroendocrine, squamous, squamous cell, hepatoid adenocarcinoma or others); 2. Gastro-esophageal junction cancer; 3. Severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months; 4. Immunosuppressive therapists for organ transplantation; 5. Seriously uncontrolled recurrent infection; 6. History of other malignancies; 7. No abilities of self-knowledge or mental disorders; 8. Combination of other serious diseases; 9. Concurrent participation in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Hepatic metastasis Predictive cancer model

Contacts and locations

Locations

  • Cancer Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.